Background
Intra-articular injections of corticosteroids (CCS), hyaluronic acid (HA), and platelet-rich plasma (PRP) have often been used for temporomandibular joint osteoarthritis (TMJ OA). However, there is no guideline for the choice of pharmacological injections. The aim of this network meta-analysis (NMA) is to compare the efficacy of different intra-articular injectable treatments on TMJ OA.
Methods
Studies were identified from PubMed, Embase and Cochrane Central with date up to December 2020. Randomized Controlled Trials (RCTs) included were the studies of patients with TMJ OA who had intra-articular treatment with CCS, HA, PRP, placebo and follow-up assessing TMJ function in target outcome variables. The primary outcome was temporomandibular joint pain (VAS). The secondary outcomes were maximal mouth opening (mm), and lateral movement to the affected side (mm).
Results
Nine RCTs involving 316 patients were included. For primary pain outcome, no significance was detected when CCS, HA and PRP were compared with placebo by both short- (3-6 months) and long-term (>12 months) follow-up. In addition, these injectables did not significantly outperform placebo by evaluating secondary functional outcomes (maximal mouth opening and lateral movement) with the same follow-up. Subgroup analyses showed that the effect of CCS on subgroups with more than 70% women was statistically less effective compared with placebo.
Conclusion
Evidence suggested that intra-articular pharmacological injections of CCS, HA, and PRP had no effect on improving TMJ pain and functional outcomes compared with placebo injection.
Trial registration
This study is registered with PROSPERO, number CRD42021270914.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.